development of a novel beta-cell replacement therapy using the adipose-tissue derived stem cell(ADSC)

利用再生药物的β细胞替代疗法有望治愈1型糖尿病。本次，我们将利用链脲佐菌素诱导的糖尿病裸鼠建立人脂肪组织源性干细胞（hADSC）移植模型，在体内研究hADSC对功能胰岛样细胞的分化和衍生影响，在体内研究hADSC对损伤胰岛细胞的归巢作用，在体外研究hADSC对损伤胰岛细胞的细胞保护作用。hADSC移植到胰腺本身分化为功能性胰岛样细胞，改善异常糖耐量。此外，尽管在体外，hADSC在没有细胞接触的情况下对胰岛细胞有保护作用，但在体内，静脉注射hADSC对损伤的胰岛细胞的归巢作用较差。

β-cell replacement therapy using regeneration medicines is expected as a cure for type 1 diabetes. This time, after the human adipose-tissue derived stem cell(hADSC) transplant model using streptozotocin-induced diabetes nude mice will be created, we investigated the differentiated and derived impact of hADSC to the functional islet like cell in vivo, the homing effect of hADSC on injured islet cell in vivo and the cell protective effects of hADSC on injured islet cell in vitro. hADSC transplanted to pancreas itself was differentiated to functional islet like cell, and improved the abnormal glucose tolerance. Moreover, although, in vitro, hADSC had an islet cell protection effect without the cell-cell contact, in vivo, the homing effect on the injured islet cell by the intravenous injection was poor.